May 15, 2018
Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development.
Drug development and clinical trials necessitate the ability to specifically, sensitively and reproducibly measure the concentration and bioavailability of these drugs in pharmacokinetic assays.
We discuss the rise of therapeutic antibodies in drug discovery in favour of traditional small molecules and issues around the development of these biologics, including their tracking with antiidiotypic antibodies. We will examine new tools that are entering the market to offer solutions that can speed development timelines and address problems of reagent reproducibility.
This article was written by Dr Robert Ford & Dr Toni Hoffmann
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: